Abstract:

Rituximab is a monoclonal antibody to the CD20 antigen on Bcells that was initially designed and approved for the treatment of nonHodgkins Bcell lymphoma,and then approved for the treatment of many immunemediated diseases which selectively targets B cells and blocks antibodies production.With the discovery of antiPLA2R and antiTHSD7A antibodies,idiopathic membranous nephropathy (IMN) has been supposed to an autoimmune disease,which provides a strong theoretical basis for the use of antiB cell therapy.Currently a growing body of literature is emerging on the benefits of rituximab in IMN.This review focuses on mechanism,clinical efficacy,monitoring item and safety of rituximab in IMN.

Key words: rituximab, idiopathic membranous nephropathy, anti-PLA2R antibodies